Phibro Animal Health Corporation (NASDAQ:PAHC) Projects Stability After Leadership Shift and Cash-Dividend Renewal

Phibro enters a near-term phase of operational continuity under new CEO Daniel M. Bendheim while financial metrics present mixed signals that support a fair-valued stance. Technical indicators show limited directional conviction but highlight short-term downside pressure with pockets of mean-reversion potential.

Recent News

On July 1, 2026 Daniel M. Bendheim assumed the role of Chief Executive Officer and President, with Jack C. Bendheim moving to Executive Chairman. On July 28, 2026 the Board declared a quarterly cash dividend of $0.12 per share, payable September 23, 2026 (record date September 2, 2026).

Technical Analysis

ADX at 20.11 indicates only an emerging trend strength, limiting conviction for a sustained directional breakout relative to the current fair-valued assessment.

DI+ at 20.96 trending down while DI- at 17.70 trending up points to a bearish directional bias in the short term, increasing the probability of lower highs against resistance levels near the 20-day average.

MACD shows a decreasing momentum profile with MACD below its signal line (MACD 0.00 vs signal 0.38), a bearish momentum reading that weakens the immediate upside case versus the stated valuation.

MRO registers -23.0 and is decreasing; the negative reading implies the price sits below the internal target, indicating mean-reversion potential that could support price recovery if momentum stabilizes.

RSI at 51.0 with a decreasing trend reflects neutral positioning that has recently softened, consistent with price trading below short- and medium-term moving averages (price $34.56 vs 20‑day average $36.73 and 50‑day average $35.35).

Price sits below the 12‑day and 26‑day EMAs (12‑day EMA $35.80; 26‑day EMA $35.91) and below the 200‑day average ($41.29), reinforcing short-term bearish pressure while Bollinger lower band proximity (1× lower $34.86) flags limited oversold room before a larger mean reversion.

Fundamental Analysis

Profitability: Operating margin stands at 11.64% and EBIT margin at 11.06%. EBIT of $42,422,000 and EBITDA of $54,870,000 show positive operating profitability, though the EBIT margin compares below the industry peer mean of 29.33% and the industry peer median of 28.17%.

Margins trended slightly lower QoQ: EBIT margin declined about 14.32% quarter-over-quarter and declined 0.76% year-over-year, signaling compression versus recent quarters despite positive absolute margins.

Earnings: Reported EPS of $0.85 beat the estimate of $0.73 by $0.12, an EPS surprise of +16.44%, reflecting better-than-expected near-term earnings execution; forward EPS sits at $0.94 with a forward P/E of 57.86.

Growth: Revenue year-over-year contracted roughly 79.34%, with quarter-over-quarter revenue down about 6.43%, indicating sharp YoY comparability effects; WMDST notes this sharp YoY decline alongside positive segment-level commentary in the annual results.

Cash flow and liquidity: Operating cash flow $16,206,000 and free cash flow $890,000 translate to a free-cash-flow yield of ~0.04%. Cash and short-term investments total $77,451,000 and the current ratio equals 3.17, providing short-term liquidity cushion despite low free cash conversion.

Leverage: Total debt $787,444,000 produces net debt of $680,587,000 against market capitalization $2,121,427,150. Debt-to-equity equals 217.63%, above the industry peer mean of 108.50%; debt-to-EBITDA rounds to 14.35, signaling elevated leverage relative to operating cash flow coverage. Interest coverage sits at 4.20, below the industry peer mean of 20.82.

Capital returns: The Board declared a quarterly cash dividend of $0.12 per share; dividend yield equals about 0.23% and the dividend payout ratio about 20.26% of earnings.

Valuation context: Price ratios show P/E ≈ 68.8 (slightly below the industry peer mean ~70.27), P/B ≈ 5.86 (slightly below the industry peer mean ~6.32), and EV/Revenue and enterprise multiple consistent with the stated WMDST valuation. WMDST values the stock as fair-valued given compressed growth, leverage profile, and mixed margin performance balanced by recent EPS outperformance.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-03-31
REPORT DATE: 2026-08-26
NEXT REPORT DATE: 2026-11-25
CASH FLOW  Begin Period Cash Flow 55.5 M
 Operating Cash Flow 16.2 M
 Capital Expenditures -15.32 M
 Change In Working Capital -26.71 M
 Dividends Paid -4.87 M
 Cash Flow Delta -557.00 K
 End Period Cash Flow 54.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 383.5 M
 Forward Revenue 152.6 M
COSTS
 Cost Of Revenue 257.9 M
 Depreciation 10.7 M
 Depreciation and Amortization 12.4 M
 Research and Development
 Total Operating Expenses 338.9 M
PROFITABILITY
 Gross Profit 125.7 M
 EBITDA 54.9 M
 EBIT 42.4 M
 Operating Income 44.7 M
 Interest Income 250.0 K
 Interest Expense 10.1 M
 Net Interest Income -10.43 M
 Income Before Tax 32.3 M
 Tax Provision 8.3 M
 Tax Rate 25.7 %
 Net Income 24.0 M
 Net Income From Continuing Operations 24.0 M
EARNINGS
 EPS Estimate 0.73
 EPS Actual 0.85
 EPS Difference 0.12
 EPS Surprise 16.438 %
 Forward EPS 0.94
 
BALANCE SHEET ASSETS
 Total Assets 1.4 B
 Intangible Assets 91.6 M
 Net Tangible Assets 270.3 M
 Total Current Assets 894.1 M
 Cash and Short-Term Investments 77.5 M
 Cash 54.9 M
 Net Receivables 221.5 M
 Inventory 539.7 M
 Long-Term Investments 21.8 M
LIABILITIES
 Accounts Payable 129.6 M
 Short-Term Debt 22.8 M
 Total Current Liabilities 281.9 M
 Net Debt 680.6 M
 Total Debt 787.4 M
 Total Liabilities 1.1 B
EQUITY
 Total Equity 361.8 M
 Retained Earnings 336.1 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 8.92
 Shares Outstanding 40.565 M
 Revenue Per-Share 9.46
VALUATION
 Market Capitalization 2.1 B
 Enterprise Value 2.8 B
 Enterprise Multiple 51.602
Enterprise Multiple QoQ 36.612 %
Enterprise Multiple YoY 74.64 %
Enterprise Multiple IPRWA high: 186.073
median: 72.06
mean: 70.858
PAHC: 51.602
low: -65.796
 EV/R 7.382
CAPITAL STRUCTURE
 Asset To Equity 3.994
 Asset To Liability 1.334
 Debt To Capital 0.685
 Debt To Assets 0.545
Debt To Assets QoQ -0.942 %
Debt To Assets YoY -6.785 %
Debt To Assets IPRWA high: 0.965
PAHC: 0.545
median: 0.372
mean: 0.363
low: 0.001
 Debt To Equity 2.176
Debt To Equity QoQ -6.448 %
Debt To Equity YoY -24.823 %
Debt To Equity IPRWA high: 2.857
PAHC: 2.176
mean: 1.085
median: 1.071
low: -0.494
PRICE-BASED VALUATION
 Price To Book (P/B) 5.863
Price To Book QoQ 20.92 %
Price To Book YoY 90.503 %
Price To Book IPRWA high: 15.559
median: 6.346
mean: 6.321
PAHC: 5.863
low: -2.867
 Price To Earnings (P/E) 68.812
Price To Earnings QoQ 50.579 %
Price To Earnings YoY 114.648 %
Price To Earnings IPRWA high: 206.5
median: 80.612
mean: 70.266
PAHC: 68.812
low: -89.846
 PE/G Ratio -5.442
 Price To Sales (P/S) 5.531
Price To Sales QoQ 28.334 %
Price To Sales YoY 135.006 %
Price To Sales IPRWA high: 42.912
mean: 24.625
median: 23.386
PAHC: 5.531
low: 0.845
FORWARD MULTIPLES
Forward P/E 57.864
Forward PE/G -4.576
Forward P/S 15.673
EFFICIENCY OPERATIONAL
 Operating Leverage -4.702
ASSET & SALES
 Asset Turnover Ratio 0.269
Asset Turnover Ratio QoQ 0.433 %
Asset Turnover Ratio YoY 0.681 %
Asset Turnover Ratio IPRWA high: 0.28
PAHC: 0.269
mean: 0.133
median: 0.123
low: 0.004
 Receivables Turnover 1.754
Receivables Turnover Ratio QoQ 1.72 %
Receivables Turnover Ratio YoY -1.859 %
Receivables Turnover Ratio IPRWA high: 2.066
PAHC: 1.754
mean: 1.235
median: 1.197
low: 0.109
 Inventory Turnover 0.488
Inventory Turnover Ratio QoQ 0.018 %
Inventory Turnover Ratio YoY -12.19 %
Inventory Turnover Ratio IPRWA high: 1.256
PAHC: 0.488
mean: 0.486
median: 0.408
low: 0.041
 Days Sales Outstanding (DSO) 52.034
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 202.212
Cash Conversion Cycle Days QoQ 7.288 %
Cash Conversion Cycle Days YoY 4.847 %
Cash Conversion Cycle Days IPRWA high: 418.272
PAHC: 202.212
mean: 169.598
median: 109.537
low: -17.659
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.626
 CapEx To Revenue -0.04
 CapEx To Depreciation -1.428
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 1.1 B
 Net Invested Capital 1.1 B
 Invested Capital 1.1 B
 Net Tangible Assets 270.3 M
 Net Working Capital 612.2 M
LIQUIDITY
 Cash Ratio 0.275
 Current Ratio 3.172
Current Ratio QoQ 3.882 %
Current Ratio YoY 8.922 %
Current Ratio IPRWA high: 7.935
PAHC: 3.172
mean: 1.185
median: 1.025
low: 0.276
 Quick Ratio 1.257
Quick Ratio QoQ 2.946 %
Quick Ratio YoY 2.257 %
Quick Ratio IPRWA high: 3.901
PAHC: 1.257
mean: 0.86
median: 0.773
low: 0.069
COVERAGE & LEVERAGE
 Debt To EBITDA 14.351
 Cost Of Debt 0.963 %
 Interest Coverage Ratio 4.196
Interest Coverage Ratio QoQ 2.971 %
Interest Coverage Ratio YoY -1.705 %
Interest Coverage Ratio IPRWA high: 54.443
mean: 20.824
median: 13.838
PAHC: 4.196
low: -48.677
 Operating Cash Flow Ratio 0.017
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 49.726
DIVIDENDS
 Dividend Coverage Ratio 4.935
 Dividend Payout Ratio 0.203
 Dividend Rate 0.12
 Dividend Yield 0.002
PERFORMANCE GROWTH
 Asset Growth Rate 2.815 %
 Revenue Growth 2.576 %
Revenue Growth QoQ -6.429 %
Revenue Growth YoY -79.342 %
Revenue Growth IPRWA high: 23.323 %
PAHC: 2.576 %
mean: -2.001 %
median: -2.044 %
low: -34.135 %
 Earnings Growth -12.644 %
Earnings Growth QoQ -165.93 %
Earnings Growth YoY -175.862 %
Earnings Growth IPRWA high: 80.0 %
median: 9.549 %
mean: -4.352 %
PAHC: -12.644 %
low: -171.429 %
MARGINS
 Gross Margin 32.767 %
Gross Margin QoQ -7.641 %
Gross Margin YoY 8.994 %
Gross Margin IPRWA high: 90.321 %
mean: 75.05 %
median: 74.423 %
PAHC: 32.767 %
low: 7.704 %
 EBIT Margin 11.061 %
EBIT Margin QoQ -14.316 %
EBIT Margin YoY -0.763 %
EBIT Margin IPRWA high: 72.336 %
mean: 29.325 %
median: 28.172 %
PAHC: 11.061 %
low: -113.582 %
 Return On Sales (ROS) 11.642 %
Return On Sales QoQ -13.5 %
Return On Sales YoY 4.45 %
Return On Sales IPRWA high: 77.585 %
mean: 31.434 %
median: 30.056 %
PAHC: 11.642 %
low: -113.597 %
CASH FLOW
 Free Cash Flow (FCF) 890.0 K
 Free Cash Flow Yield 0.042 %
Free Cash Flow Yield QoQ -91.797 %
Free Cash Flow Yield YoY -99.029 %
Free Cash Flow Yield IPRWA high: 8.308 %
mean: 0.935 %
median: 0.606 %
PAHC: 0.042 %
low: -7.735 %
 Free Cash Growth -89.219 %
Free Cash Growth QoQ -68.505 %
Free Cash Growth YoY -89.455 %
Free Cash Growth IPRWA high: 242.307 %
mean: -14.323 %
median: -44.294 %
PAHC: -89.219 %
low: -213.333 %
 Free Cash To Net Income 0.037
 Cash Flow Margin 1.25 %
 Cash Flow To Earnings 0.2
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 1.685 %
Return On Assets QoQ -14.38 %
Return On Assets YoY 5.05 %
Return On Assets IPRWA high: 8.812 %
mean: 3.037 %
median: 2.701 %
PAHC: 1.685 %
low: -20.654 %
 Return On Capital Employed (ROCE) 3.647 %
 Return On Equity (ROE) 0.066
Return On Equity QoQ -19.632 %
Return On Equity YoY -15.414 %
Return On Equity IPRWA high: 0.239
mean: 0.088
PAHC: 0.066
median: 0.065
low: -0.557
 DuPont ROE 6.922 %
 Return On Invested Capital (ROIC) 2.872 %
Return On Invested Capital QoQ -16.072 %
Return On Invested Capital YoY 4.627 %
Return On Invested Capital IPRWA high: 14.677 %
mean: 5.786 %
median: 4.113 %
PAHC: 2.872 %
low: -9.485 %

Six-Week Outlook

Expect limited trend conviction in the coming six weeks. Technicals favor short-term downside pressure while MRO’s negative reading supports mean-reversion upside if momentum stabilizes above the 50‑day average. Near-term drivers include any further commentary from management under the new CEO, dividend flow, and updates to guidance; with leverage and cash conversion remaining focal fundamental risks, price action should remain range-bound between resistance near the 20‑day average and support just below the lower Bollinger band. Monitor momentum indicators for signs of MACD stabilization above its signal line and an ADX pickup to validate a directional move aligned with the WMDST fair-valued view.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation (NASDAQ:PAHC) develops, manufactures, and markets a wide range of products designed to enhance the health and nutrition of animals. Operating through three distinct segments—Animal Health, Mineral Nutrition, and Performance Products—the company serves a diverse array of customers worldwide, including those in the United States, Israel, Brazil, Ireland, and other international markets. In the Animal Health segment, Phibro produces antibacterials, anticoccidials, nutritional specialties, and vaccines aimed at improving the health and performance of food and companion animals such as poultry, swine, cattle, aquaculture species, and dogs. The company also manufactures microbial and bioproducts for animal health and nutrition, as well as for environmental and industrial applications. The Mineral Nutrition segment offers trace minerals like zinc, manganese, copper, and iron, which fortify livestock diets and maintain optimal trace element balance. Additionally, Phibro’s Performance Products segment provides specialty ingredients for the personal care, industrial chemical, and chemical catalyst industries. Founded in 1946 and headquartered in Teaneck, New Jersey, Phibro Animal Health Corporation distributes its products through local sales offices, commercial animal feed manufacturers, wholesalers, and distributors.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.